基于生命体征轨迹的新型脓毒症亚表型的开发与验证
本研究在Emory Healthcare四家学术医院中,对2014-2017年疑似感染患者(训练队列)和2018-2019年患者(验证队列)应用基于组的轨迹模型分析入院8小时生命体征,开发并验证了4个生命体征轨迹亚表型。在6919例脓毒症患者中,A组和D组30天死亡率显著更高,A组和D组血管加压药使用最多。在SMART试验二次分析中,亚表型显著修饰平衡晶体液与生理盐水的疗效(p=0.03),D组使用平衡晶体液较生理盐水死亡风险显著降低(OR 0.39, 95%CI 0.23-0.67, p<0.001)。
要点
- 在6919例脓毒症患者中,基于入院8小时生命体征轨迹识别出4个亚表型,A组(高热、心动过速、呼吸急促、低血压)和D组(低体温、低心率、低呼吸频率、低血压)30天死亡率显著更高(分别为p<0.001和p=0.03)。
- SMART试验二次分析显示,亚表型显著修饰平衡晶体液与生理盐水的疗效(p=0.03);D组使用平衡晶体液较生理盐水死亡风险显著降低(OR 0.39, 95%CI 0.23-0.67, p<0.001)。
- A组和D组血管加压药使用率最高(p<0.001);A组心力衰竭、高血压、糖尿病和慢性肾脏病患病率最低,B组最高。
- A组和B组患者较年轻,C组和D组患者年龄较大。
适用人群与场景
- 2014-2017年Emory Healthcare四家学术医院收治的疑似感染患者(训练队列,12473例)及2018-2019年收治的疑似感染患者(验证队列,8256例)。
- 脓毒症患者6919例用于评估亚表型与结局的关联。
- SMART试验(Isotonic Solutions and Major Adverse Renal Events Trial)人群用于亚表型与治疗交互作用分析。
诊断标准与关键阈值
- 基于入院后前8小时生命体征,应用基于组的轨迹模型(group-based trajectory modeling)识别出4个生命体征轨迹亚表型。
- A组(N=3483,28%):高热、心动过速、呼吸急促、低血压。
- B组(N=1578,13%):高热、心动过速、呼吸急促(不如A组显著)、高血压。
- C组(N=4044,32%):较低体温、心率和呼吸频率,血压正常。
- D组(N=3368,27%):较低体温、心率和呼吸频率,低血压。
处置流程与药物剂量
- SMART试验中,D组使用平衡晶体液较生理盐水死亡风险显著降低(OR 0.39, 95%CI 0.23-0.67, p<0.001)。
红旗征与不能漏的情况
- A组(高热、心动过速、呼吸急促、低血压)和D组(低体温、低心率、低呼吸频率、低血压)30天死亡率显著更高(分别为p<0.001和p=0.03)。
- A组和D组血管加压药使用率最高(p<0.001)。
研究设计与关键结果
- 研究类型:基于电子健康记录的队列研究,开发与验证生命体征轨迹亚表型,并对SMART试验进行二次分析。
- 训练队列12473例疑似感染患者,验证队列8256例疑似感染患者,共识别出4个生命体征轨迹亚表型。
- 在6919例脓毒症患者中,A组和B组较年轻,C组和D组年龄较大;A组心力衰竭、高血压、糖尿病、慢性肾脏病患病率最低,B组最高;A组和D组血管加压药使用最多(p<0.001)。
- 逻辑回归显示,A组和D组30天死亡率显著更高(p<0.001和p=0.03)。
- SMART试验中,亚表型显著修饰平衡晶体液与生理盐水的疗效(p=0.03);D组使用平衡晶体液较生理盐水死亡风险显著降低(OR 0.39, 95%CI 0.23-0.67, p<0.001)。
证据类型、等级与局限
- 证据类型:观察性队列研究(开发与验证队列)及随机对照试验(SMART)二次分析。
- 局限:原文未报告局限性
对床旁实践的改变
- 基于生命体征轨迹的脓毒症亚表型在不同队列中一致,具有不同的结局和对平衡晶体液与生理盐水的不同反应。
- 在SMART试验中,D组(低体温、低心率、低呼吸频率、低血压)使用平衡晶体液较生理盐水死亡风险显著降低(OR 0.39, 95%CI 0.23-0.67, p<0.001)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Sepsis is a heterogeneous syndrome and identification of sub-phenotypes is essential. This study used trajectories of vital signs to develop and validate sub-phenotypes and investigated the interaction of sub-phenotypes with treatment using randomized controlled trial data.
METHODS: All patients with suspected infection admitted to four academic hospitals in Emory Healthcare between 2014-2017 (training cohort) and 2018-2019 (validation cohort) were included. Group-based trajectory modeling was applied to vital signs from the first 8 h of hospitalization to develop and validate vitals trajectory sub-phenotypes. The associations between sub-phenotypes and outcomes were evaluated in patients with sepsis. The interaction between sub-phenotype and treatment with balanced crystalloids versus saline was tested in a secondary analysis of SMART (Isotonic Solutions and Major Adverse Renal Events Trial).
RESULTS: There were 12,473 patients with suspected infection in training and 8256 patients in validation cohorts, and 4 vitals trajectory sub-phenotypes were found. Group A (N = 3483, 28%) were hyperthermic, tachycardic, tachypneic, and hypotensive. Group B (N = 1578, 13%) were hyperthermic, tachycardic, tachypneic (not as pronounced as Group A) and hypertensive. Groups C (N = 4044, 32%) and D (N = 3368, 27%) had lower temperatures, heart rates, and respiratory rates, with Group C normotensive and Group D hypotensive. In the 6,919 patients with sepsis, Groups A and B were younger while Groups C and D were older. Group A had the lowest prevalence of congestive heart failure, hypertension, diabetes mellitus, and chronic kidney disease, while Group B had the highest prevalence. Groups A and D had the highest vasopressor use (p < 0.001 for all analyses above). In logistic regression, 30-day mortality was significantly higher in Groups A and D (p < 0.001 and p = 0.03, respectively). In the SMART trial, sub-phenotype significantly modified treatment effect (p = 0.03). Group D had significantly lower odds of mortality with balanced crystalloids compared to saline (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.23-0.67, p < 0.001).
CONCLUSION: Sepsis sub-phenotypes based on vital sign trajectory were consistent across cohorts, had distinct outcomes, and different responses to treatment with balanced crystalloids versus saline.
参考来源
- Bhavani SV, Semler M, Qian ET, et al. Development and validation of novel sepsis subphenotypes using trajectories of vital signs. Intensive Care Med. 2022. PMID: 36152041. doi:10.1007/s00134-022-06890-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。